Cellartgen

Cellartgen is a South Korean biotechnology company focused on personalized regenerative medicine and drug discovery through the integration of organoid and advanced biomaterial technologies. The company develops "bio-organs" that structurally and functionally mimic real human organs, utilizing proprietary decellularization and microfluidic technologies to overcome the limitations of animal testing. Cellartgen's core product line, Regenix™, consists of organ-specific extracellular matrix (ECM) hydrogels (including liver, intestine, skin, lung, heart, and kidney) that serve as biomimetic scaffolds for 3D cell culture, organoid maturation, and tissue transplantation. Additionally, the company offers organoid-based drug evaluation services for intractable diseases such as nonalcoholic steatohepatitis (NASH), Alzheimer's disease, and idiopathic pulmonary fibrosis (IPF), alongside developing lipid nanoparticle (LNP) delivery systems and genetic reprogramming therapies.